



SALE OF GCL PHARMA FINALIZED FULL FOCUS ON CORE BUSINESS

Alessandria, 16 April 2020 - Guala Closures S.p.A., the world leader in the production of security closures for spirits and aluminum closures for wines and one of the major global producers and distributors of aluminum closures for the beverage industry, announces the finalization of the sale of 100% GCL Pharma S.r.l to the Bormioli Pharma Group S.p.A..

Based on an Enterprise Value of Euro 10 million, the consideration for the sale of 100% of GCL Pharma S.r.l. amounts to Euro 9.3 million, of which Euro 7.3 million has just been received, with the remainder due within 12 months. The entire amount will reduce the Group's debt.

Marco Giovannini, Chairman and CEO of Guala Closures Group, commented: "This disposal will allow the Guala Closures Group to continue to focus even more on the core business and specifically on closures with higher added-value and better growth prospects, including connected closures which allow interaction through a microchip and bottles to be tracked. As for 2020, our strategy will be focused on cash generation, the consolidation of the Scottish company UCP (acquired in December 2018), the integration of the German assets of Closurelogic (purchased in February 2020, with the aim of rapidly maximizing integration synergies) and on the reduction of Group debt".

Andrea Lodetti, CEO of Bormioli Pharma, commented: "We are proud to welcome our new colleagues in Bormioli Pharma Group. This acquisition allows us to expand and complete our offer of primary pharmaceutical packaging, especially for the parenteral applications, and brings along new technologies and professional expertise. We are planning significant industrial investments for our plant in Vasto, in order to boost the development and activation of operational and commercial synergies and increase the level of service to our customers".

Guala Closures Group

Guala Closures Group has more than 4,700 employees and operates in 5 continents through 30 production plants and markets its products in over 100 countries. Today the Group sells nearly 20 billion closures yearly, with a 2019 turnover of 607 million Euros. Thanks to a policy of continuous business development and technological innovation, the Group is recognized as a global point of reference in the production of alcohol safety closures and is a leading manufacturer of aluminium closures for spirits, wines and beverages.

From August 2018, Guala Closures S.p.A. has been listed on the STAR segment of the Italian Stock Exchange, entering the FTSE Italia Mid Cap index in September 2019.

Find out more on www.gualaclosures.com

About Bormioli Pharma

Bormioli Pharma operates in close partnership with the pharmaceutical industry and with all the businesses that are engineering the future of healthcare. As a world-renowned player in the packaging industry, Bormioli Pharma serves the pharmaceutical and biopharmaceutical market with integrated glass and plastic containers, closures, and packaging accessories using state-of-the-art materials and technologies. Each product is a unique combination of rigorous studies, cutting-edge technology, extreme testing, advanced industrial processes, and the finest materials.

As a partner to the pharmaceutical industry, Bormioli Pharma invests and innovates with one goal in mind: improving people's lives. Bormioli Pharma employees over 1200 people, produces 6.5 billion pieces every year and had an annual turnover of approximately €250 million in 2019.

**Investor Relations**

Guala Closures S.p.A.

Alessandro Baj Badino

Tel +39 0131 753281

abajbadino@gclinternational.com

Media Relations

True Relazioni Pubbliche

Federica Menichino – +39 349 6976982 – f.menichino@true-rp.it

Pietro Ferreri – +39 331 9019581 – p.ferreri@true-rp.it